Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

KEYNOTE-040 investigators

    Research output: Contribution to journalArticlepeer-review

    673 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study'. Together they form a unique fingerprint.

    Medicine & Life Sciences